This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -5.00% and -3.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q3 results on Oct 30.
Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
by Zacks Equity Research
Earnings releases and key data-read outs were the key developments in the biotech sector last week.
Incyte (INCY) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales
by Zacks Equity Research
Incyte's (INCY) performance is likely to be strong due to rising demand of lead drug, Jakafi.
5 Reasons Why Investors Should Bet on Merck (MRK) Stock
by Zacks Equity Research
Here are some reasons why investors may consider putting their money into Merck (MRK) stock.
Agenus Receives Milestone Payment of $5 Million from Incyte
by Zacks Equity Research
Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.
Merck Gets Priority Review for Yet Another Keytruda sBLA
by Zacks Equity Research
Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
by Zacks Equity Research
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Incyte, Foundation Medicine Partner for Companion Diagnostics
by Zacks Equity Research
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.
Merck's Keytruda Gets Priority Review for Rare Skin Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.
Why Is Incyte (INCY) Up 12.9% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.
Agenus (AGEN) Delivering Well on Its Pipeline Candidates
by Zacks Equity Research
We have issued an updated report on Agenus (AGEN) highlighting updates on its pipeline candidates.
Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release
by Zacks Equity Research
Merck's (MRK) stock is up 4.2% since announcement of earnings in July. Let us have a look at the reasons for the same.
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2
by Zacks Equity Research
Incyte's (INCY) Q2 results were a mixed bag with earnings missing estimates, while revenues beating the same with growth in Jakafi's sales. A milestone payment from Eli Lilly boosted sales as well.
Incyte (INCY) Lags Q2 Earnings Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -13.33% and 12.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT
by Zacks Equity Research
Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte (INCY) has a mixed track record. Investors will focus on Jakafi sales and other pipeline updates when the company reports its Q2 results on Jul 31.
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
by Zacks Equity Research
CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Merck's Keytruda Gets Priority Review in Difficult Lung Cancer
by Zacks Equity Research
Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.
Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod
by Zacks Equity Research
The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.